Defence Therapeutics Inc.

Canadian Sec Stock Exchange DTC.CN

Defence Therapeutics Inc. Revenue for the year ending June 30, 2024: USD 0.00

Defence Therapeutics Inc. Revenue is USD 0.00 for the year ending June 30, 2024, a 0.00% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.
  • Defence Therapeutics Inc. Revenue for the year ending June 30, 2023 was USD 0.00, a 0.00% change year over year.
  • Defence Therapeutics Inc. Revenue for the year ending June 30, 2022 was USD 0.00, a 0.00% change year over year.
  • Defence Therapeutics Inc. Revenue for the year ending June 30, 2021 was USD 0.00, a 0.00% change year over year.
  • Defence Therapeutics Inc. Revenue for the year ending June 30, 2020 was USD 0.00, a 0.00% change year over year.
Key data
Date Revenue Gross Profit Operating Income EBIT
Market news
SV Wall Street
Canadian Sec Stock Exchange: DTC.CN

Defence Therapeutics Inc.

CEO Mr. Sebastien Plouffe
IPO Date May 10, 2021
Location Canada
Headquarters 1680 – 200 Burrard Street
Employees 5
Sector Healthcare
Industries
Biotechnology 3D Printing Pharmaceuticals Plastics Vaccines
Description

Defence Therapeutics Inc., a biotechnology company, engages in the research and development of biological/biosimilar therapeutic drugs for cancer and infectious diseases. Its proprietary platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. The company focuses on developing dendritic cell cancer vaccines; protein-based vaccine formulation against COVID and infectious diseases; and antibody drug conjugates (ADC) products targeting various cancers. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. Defence Therapeutics Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.

StockViz Staff

February 6, 2025

Any question? Send us an email